Vertex Pharma (VRTX) Tops Q1 EPS by 68c; reiterates guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- AMD forecast eases AI spending fears as data-center sales surge
- Moderna shares rise ahead of Thursday earnings report
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Vertex (VRTX) PT Raised to $424 at RBC Capital
May 7, 2024 6:21 AM EDTRBC Capital analyst Brian Abrahams raised the price target on Vertex (NASDAQ: VRTX) to $424.00 (from $417.00) while maintaining a Sector Perform rating.
The analyst comments "A solid 1Q optically, with WW CF sales exceeding expectations, though this was driven mainly by ex-U.S.... More
Vertex (VRTX) PT Lowered to $-- at Stifel
May 7, 2024 6:13 AM EDTStifel analyst Paul Matteis lowered the price target on Vertex (NASDAQ: VRTX) to $-- (from $430.00) while maintaining a Hold rating.
The analyst comments "We remain Hold rated on VRTX. The CF franchise posted a beat (helped by inventory) while VRTX reiterated their... More



